FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Turtle Cameron (Last) (First) (Middle) C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET (Street) PALO ALTO CA 94301						2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO] 3. Date of Earliest Transaction (Month/Day/Year) 06/30/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) See Remarks 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)			Person													
		Tab	le I - I	Non-Deri	vative	Sec	uriti	es A	cquire	ed, D	isposed o	of, or B	enefic	ially	Owned	t			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		2. Transact Date (Month/Day		Execution Date,		ution Date,		ction Instr.		Acquired (A) or (D) (Instr. 3, 4 and		d 5) Secu Bene Own		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock			06/30/2	020)20					6,000	A	\$ <mark>0</mark> .1	16	15	5,823		D		
Common Stock 06/3			06/30/2	020	20			M		4,000	A	\$0.3	34	19	19,823		D		
Common Stock 06/30/2			020	20		S		9,700	D	\$32.64	32.6465(1)		10,123		D				
Common Stock 06/30/202				020	20		S		300	D	\$33.17	33.1733(2)		9,823		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		cisable and	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. De Se	3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly OF	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$0.16	06/30/2020			M			6,000	05/19	/2020	05/23/2029	Common Stock	6,00	0	\$0.00	68,042		D	
Stock Option (Right to Buy)	\$0.34	06/30/2020			M			4,000	05/19	/2020	07/14/2029	Common Stock	ⁿ 4,00	0	\$0.00	45,766	5	D	

Explanation of Responses:

1. Represents the weighted average sale price of the shares sold from \$32.12 to \$33.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2.

2. Represents the weighted average sale price of the shares sold from \$33.13 to \$33.23 per share.

Senior Vice President, Portfolio Management and Corporate Development

/s/ Tara Condon, Attorney-in-

07/02/2020

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.